106 research outputs found
Oxigenoterapia y cuidados paliativos en pacientes con insuficiencia cardiaca. Respuesta
Letter to the Edito
ASIC para sistemas de medidas ambientales
El circuito integrado que aquí se describe ha sido diseñado con tecnología puramente digital, y tiene como función servir como centro concentrador de datos en estaciones meteorológicas, aunque por su diseño genérico puede ser usado en cualquier otro campo. Su objetivo principal es la adquisición de medidas (condiciones ambientales como velocidad y dirección del viento, tempera-turas, humedades relativas,...) y la generación de señales analógicas y digitales telemandadas procedentes de un canal de radio o de un canal SPI. Esta realización se enmarca dentro del programa GAME y ha sido desarrollada en colaboración con la empresa SAINCO
Adquisición de datos digitales con protocolo VME sobre FPGA
En este artículo se presenta la realización sobre FPGA de un circuito con 16 filtros digitales. Un cambio en la entrada es validado cada vez que tres muestras consecutivas toman el mismo valor. El dato muestreado es accesible mediante protocolo VME estándar, incluyendo daisy-cbain para la gestión de interrupciones. El circuito de acceso VME se ha descrito en lenguaje de comportamiento VERILOG-XL, y sintetizado usando SYNERGY. El resto del circuito ha sido capturado y simulado empleando el entorno de diseño Framework II de Cadence. El circuito ha sido programado en una FPGA 1020A de Texas Instrument. Como resultado se ha obtenido una tarjeta de adquisición de datos con una densidad de componentes muy baja, y que está siendo actualmente empleada en sistemas de control industriales
Circuito ASIC para enlaces rápidos de comunicaciones por fibra óptica
El circuito integrado que aquí se describe ha sido diseñado con tecnología puramente digital, y tiene como función servir de interfase entre 8 enlaces rápidos de comunicaciones por fibra óptica y un procesador local que utiliza protocolo VME. Este trabajo se enmarca dentro del programa GAME y ha sido desarrollado en colaboración con la empresa SAINCO
Documento de consenso y recomendaciones sobre cuidados paliativos en insuficiencia cardiaca de las Secciones de Insuficiencia Cardiaca y Cardiología Geriátrica de la Sociedad Española de Cardiología
Review[Abstract] Heart failure is a complex entity, with high morbidity and mortality. The clinical course and outcome are uncertain and difficult to predict. This document, instigated by the Heart Failure and Geriatric Cardiology Working Groups of the Spanish Society of Cardiology, addresses various aspects related to palliative care, where most cardiovascular disease will eventually converge. The document also establishes a consensus and a series of recommendations with the aim of recognizing and understanding the need to implement and progressively apply palliative care throughout the course of the disease, not only in the advanced stages, thus improving the care provided and quality of life. The purpose is to improve and adapt treatment to the needs and wishes of each patient, who must have adequate information and participate in decision-making.[Resumen] La insuficiencia cardiaca es una entidad compleja, que conlleva elevada morbilidad y mortalidad y cuyo curso y evolución son inciertos y difíciles de predecir. Este trabajo, impulsado por las Secciones de Insuficiencia Cardiaca y Cardiología Geriátrica de la Sociedad Española de Cardiología, aborda los diferentes aspectos relacionados con los cuidados paliativos en el campo de la insuficiencia cardiaca, vía final común de la mayoría de las enfermedades cardiovasculares. También establece un consenso y una serie de recomendaciones con el objetivo de reconocer y comprender la necesidad de implementar y aplicar, de modo progresivo, este tipo de cuidados a lo largo del curso de la enfermedad, y no únicamente en sus estadios avanzados, para mejorar la atención que reciben los pacientes y su calidad de vida. La finalidad es mejorar y adecuar los tratamientos a las necesidades y los deseos de cada paciente, que debe contar con información adecuada y ser partícipe de la toma de decisiones
Determinants of Maximal Oxygen Uptake in Patients With Heart Failure
[Abstract] Aims Maximum oxygen uptake (VO₂max) is an essential parameter to assess functional capacity of patients with heart failure (HF). We aimed to identify clinical factors that determine its value, as they have not been well characterized yet. Methods We conducted a retrospective, observational, single‐centre study of 362 consecutive patients with HF who underwent cardiopulmonary exercise testing (CPET) as part of standard clinical assessment since 2009–2019. CPET was performed on treadmill, according to Bruce's protocol (n = 360) or Naughton's protocol (n = 2). We performed multivariable linear regression analyses in order to identify independent clinical predictors associated with peak VO₂max. Results Mean age of study patients was 57.3 ± 10.9 years, mean left ventricular ejection fraction was 32.8 ± 14.2%, and mean VO₂max was 19.8 ± 5.2 mL/kg/min. Eighty‐nine (24.6%) patients were women, and 114 (31.5%) had ischaemic heart disease. Multivariable linear regression analysis identified six independent clinical predictors of VO₂max, including NYHA class (B coefficient = −2.585; P < 0.001), age (B coefficient per 1 year = −0.104; P < 0.001), tricuspid annulus plane systolic excursion (B coefficient per 1 mm = +0.209; P < 0.001), body mass index (B coefficient per 1 kg/m² = −0.172; P = 0.002), haemoglobin (B coefficient per 1 g/dL = +0.418; P = 0.007) and NT‐proBNP (B coefficient per 1000 pg/mL = −0.142; P = 0.019). Conclusions The severity of HF (NYHA class, NT‐proBNP) as well as age, body composition and haemoglobin levels influence significantly exercise capacity. In patients with HF, the right ventricular systolic function is of greater importance for the physical capacity than the left ventricular systolic function
Expression of epicardial adipose tissue thermogenic genes in patients with reduced and preserved ejection fraction heart failure
[Abstract] Epicardial adipose tissue has been proposed to participate in the pathogenesis of heart failure. The aim of our study was to assess the expression of thermogenic genes (Uncoupling protein 1 (UCP1), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), and PR-domain-missing 16 (PRDM16) in epicardial adipose tissue in patients with heart failure, stablishing the difference according to left ventricular ejection fraction (reduced or preserved). Among the 75 patients in our study, 42.7% (n=32) had reduced left ventricular ejection fraction. UCP1, PGC1α and PRDM16 mRNA in EAT were significantly lower in patients with reduced left ventricular ejection fraction. Multiple regression analysis showed that age, male gender, body max index, presence of obesity, type-2-diabetes mellitus, hypertension and coronary artery disease and left ventricular ejection fraction were associated with the expression levels of UCP1, PGC1α and PRDM16 mRNA. Thermogenic genes expressions in epicardial adipose tissue (UCP1: OR 0.617, 95%CI 0.103-0.989, p=0.042; PGC1α: OR 0.416, 95%CI 0.171-0.912, p=0.031; PRDM16: OR 0.643, 95%CI 0.116-0.997, p=0.044) were showed as protective factors against the presence of heart failure with reduced left ventricular ejection fraction, and age (OR 1.643, 95%CI 1.001-3.143, p=0.026), presence of coronary artery disease (OR 6.743, 95%CI 1.932-15.301, p<0.001) and type-2-diabetes mellitus (OR 4.031, 95%CI 1.099-7.231, p<0.001) were associated as risk factors. The adequate expression of thermogenic genes has been shown as possible protective factors against heart failure with reduced ejection fraction, suggesting that a loss of functional epicardial adipose tissue brown-like features would participate in a deleterious manner on heart metabolism. Thermogenic genes could represent a future novel therapeutic target in heart failure.Ministerio de Salud, Servicios Sociales e Igualdad; PI13/02542Ministerio de Salud, Servicios Sociales e Igualdad; PI11/01661Red de Investigación Cardiovascular (España), RD12/0042/003
Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.
Background:
Chronic anticoagulation with vitamin K antagonists (VKAs) is recommended in patients
with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral
anticoagulants (NOACs) are an alternative to VKAs but there are limited data to
support their use in HCM. We sought to describe the pattern of use, thromboembolic
events, bleeding and quality of life in patients with HCM and AF treated with NOACs.
Methods:
Data from patients treated with NOACs (n=99) and VKA (n=433) at 9 inherited cardiac
diseases units were retrospectively collected. Annual rates of embolic events, serious
bleeding and death were analysed and compared. Quality of life and treatment
satisfaction were evaluated with SF-36 and SAFUCA questionnaires in 80 NOAC-treated
and 57 VKA-treated patients.
Results:
After median follow-up of 63 months (IQR:26–109), thromboembolic events
(TIA/stroke and peripheral embolism) occurred in 10% of patients on oral
anticoagulation. Major/clinically relevant bleeding occurred in 3.8% and the global
mortality rate was 23.3%. Thromboembolic event rate was 0.62 per 100 patient-years
in the NOAC group vs. 1.59 in the VKA group [subhazard ratio (SHR) 0.32;95%CI:0.04–
2.45;p=0.27]. Major/clinically relevant bleeding occurred in 0.62 per 100 person-years
in the NOAC group vs. 0.60 in the VKA group (SHR 1.28;95%CI 0.18–9.30;p=0.85). Quality of life scores were similar in both groups; however, NOAC-treated patients
achieved higher scores in the SAFUCA.
Conclusions:
HCM patients with AF on NOACs showed similar embolic and bleeding rates to those
on VKA. Although quality of life was similar in both groups, the NOAC group reported
higher treatment satisfaction.pre-print929 K
Beyond visual acuity: Patient-relevant assessment measures of visual function in retinal diseases
Purpose: To identify patient-reported outcomes (PROs) and other clinical outcome measures (contrast sensitivity (CS), low-luminance visual acuity (LLVA) and reading acuity or reading speed (RA-RS)), relevant to patients with age-related macular degeneration (AMD) or diabetic retinopathy (DR), which would be recommended for use in clinical practice.
Methods: The RAND/UCLA Appropriateness Method, based on the synthesis of the scientific evidence and the collective judgment of an expert panel using the two-round Delphi method, was applied. The evidence synthesis was performed by searching for articles on outcome measures for AMD and/or DR published between 2005 and 2018 in English or Spanish. The expert panel consisted of 14 Spanish ophthalmologists, who rated the recommendation degree for each outcome measure on a scale of 1 (extremely irrelevant) to 9 (maximum relevance). The recommended outcome measures were established according to the panel median score and the level of the panelists’ agreement.
Results: Through the evidence search, 33 PRO-specific questionnaires (21 for visual function, six for AMD, three for DR, one for AMD and DR) and two treatment satisfaction questionnaires (one on AMD and one on DR) were identified. In addition, 21 methods were found for measuring CS, five for LLVA, and nine for RA-RS. According to the panel ratings, 11 of the 64 outcome measures evaluated for AMD, and seven of the 61 evaluated for DR were recommended.
Conclusion: The AMD and DR outcome measures recommended will help ophthalmologists choose the outcome measure most appropriate for their patients. Furthermore, the use of PROs will contribute to shifting clinical practice towards patient-centered medicine
Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS)
Aims: The role of non-invasive telemedicine (TM) combining telemonitoring and teleintervention by videoconference (VC) in patients recently admitted due to heart failure (HF) ('vulnerable phase' HF patients) is not well established. The aim of the Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS) trial is to assess the impact on clinical outcomes of implementing a TM service based on mobile health (mHealth), which includes remote daily monitoring of biometric data and symptom reporting (telemonitoring) combined with VC structured, nurse-based follow-up (teleintervention). The results will be compared with those of the comprehensive HF usual care (UC) strategy based on face-to-face on-site visits at the vulnerable post-discharge phase. Methods and results: We designed a 24 week nationwide, multicentre, randomized, controlled, open-label, blinded endpoint adjudication trial to assess the effect on cardiovascular (CV) mortality and non-fatal HF events of a TM-based comprehensive management programme, based on mHealth, for patients with chronic HF. Approximately 508 patients with a recent hospital admission due to HF decompensation will be randomized (1:1) to either structured follow-up based on face-to-face appointments (UC group) or the delivery of health care using TM. The primary outcome will be a composite of death from CV causes or non-fatal HF events (first and recurrent) at the end of a 6 month follow-up period. Key secondary endpoints will include components of the primary event analysis, recurrent event analysis, and patient-reported outcomes. Conclusions: The HERMeS trial will assess the efficacy of a TM-based follow-up strategy for real-world 'vulnerable phase' HF patients combining telemonitoring and teleintervention
- …